Do analysts rate IMDX or TCRT?

Oncocyte currently has a consensus price target of $12.00, indicating a potential upside of 120.59%. Given Oncocyte's stronger consensus rating and higher probable upside, equities research analysts plainly believe Oncocyte is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncocyte 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer TCRT or CGEN?

Compugen has a consensus target price of $5.00, suggesting a potential upside of 148.76%. Given Compugen's stronger consensus rating and higher possible upside, analysts clearly believe Compugen is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Compugen 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Do analysts recommend JMAC or TCRT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, JMAC or TCRT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A

Is JMAC or TCRT more profitable?

Maxpro Capital Acquisition's return on equity of 0.00% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maxpro Capital Acquisition N/A N/A N/A Alaunos Therapeutics N/A -165.94% -123.50%

Do analysts recommend ARTV or TCRT?

Artiva Biotherapeutics currently has a consensus target price of $39.00, indicating a potential upside of 297.15%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Artiva Biotherapeutics is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ARTV or TCRT more profitable?

Artiva Biotherapeutics' return on equity of -73.15% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -73.15% -62.74% Alaunos Therapeutics N/A -165.94% -123.50%

Do analysts rate MDWD or TCRT?

MediWound currently has a consensus price target of $34.00, indicating a potential upside of 138.76%. Given MediWound's stronger consensus rating and higher possible upside, analysts clearly believe MediWound is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediWound 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Alaunos Therapeutics (TCRT) Competitors

$2.15 -0.07 (-3.15%)

Closing price 04:00 PM Eastern

Extended Trading

$2.33 +0.18 (+8.56%)

As of 07:53 PM Eastern

Compare

TCRT vs. IMDX, CGEN, JMAC, ARTV, and MDWD

Should you buy Alaunos Therapeutics stock or one of its competitors? MarketBeat compares Alaunos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alaunos Therapeutics include Oncocyte (IMDX), Compugen (CGEN), Maxpro Capital Acquisition (JMAC), Artiva Biotherapeutics (ARTV), and MediWound (MDWD). These companies are all part of the "pharmaceutical products" industry.

How does Alaunos Therapeutics compare to Oncocyte?

Oncocyte (NASDAQ:IMDX) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

55.4% of Oncocyte shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 2.2% of Oncocyte shares are held by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Oncocyte has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.07, meaning that its share price is 207% less volatile than the broader market.

Alaunos Therapeutics has lower revenue, but higher earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	43.37	-$50.22M	-$1.48	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A

In the previous week, Oncocyte had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 1 mentions for Oncocyte and 0 mentions for Alaunos Therapeutics. Oncocyte's average media sentiment score of 0.21 beat Alaunos Therapeutics' score of 0.00 indicating that Oncocyte is being referred to more favorably in the media.

Company	Overall Sentiment
Oncocyte	Neutral
Alaunos Therapeutics	Neutral

Alaunos Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,454.64%	N/A	-96.96%
Alaunos Therapeutics	N/A	-165.94%	-123.50%

Oncocyte currently has a consensus price target of $12.00, indicating a potential upside of 120.59%. Given Oncocyte's stronger consensus rating and higher probable upside, equities research analysts plainly believe Oncocyte is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Oncocyte beats Alaunos Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Compugen?

Alaunos Therapeutics (NASDAQ:TCRT) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, Compugen had 4 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 4 mentions for Compugen and 0 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.00 equaled Compugen'saverage media sentiment score.

Company	Overall Sentiment
Alaunos Therapeutics	Neutral
Compugen	Neutral

Alaunos Therapeutics has a beta of -1.07, suggesting that its stock price is 207% less volatile than the broader market. Comparatively, Compugen has a beta of 2.74, suggesting that its stock price is 174% more volatile than the broader market.

Compugen has a net margin of 47.97% compared to Alaunos Therapeutics' net margin of 0.00%. Compugen's return on equity of 47.72% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Compugen	47.97%	47.72%	27.51%

Compugen has higher revenue and earnings than Alaunos Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A
Compugen	$72.76M	2.61	$35.34M	$0.37	5.43

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Compugen has a consensus target price of $5.00, suggesting a potential upside of 148.76%. Given Compugen's stronger consensus rating and higher possible upside, analysts clearly believe Compugen is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Compugen beats Alaunos Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Maxpro Capital Acquisition?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

In the previous week, Maxpro Capital Acquisition's average media sentiment score of 0.00 equaled Alaunos Therapeutics'average media sentiment score.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Alaunos Therapeutics	Neutral

Maxpro Capital Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.07, indicating that its stock price is 207% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A

Maxpro Capital Acquisition's return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Alaunos Therapeutics	N/A	-165.94%	-123.50%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Maxpro Capital Acquisition beats Alaunos Therapeutics on 5 of the 6 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Artiva Biotherapeutics has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.07, suggesting that its stock price is 207% less volatile than the broader market.

In the previous week, Artiva Biotherapeutics had 10 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 10 mentions for Artiva Biotherapeutics and 0 mentions for Alaunos Therapeutics. Artiva Biotherapeutics' average media sentiment score of 1.33 beat Alaunos Therapeutics' score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Artiva Biotherapeutics	Positive
Alaunos Therapeutics	Neutral

Artiva Biotherapeutics currently has a consensus target price of $39.00, indicating a potential upside of 297.15%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Artiva Biotherapeutics is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Artiva Biotherapeutics' return on equity of -73.15% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
Alaunos Therapeutics	N/A	-165.94%	-123.50%

Alaunos Therapeutics has lower revenue, but higher earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	971.00	-$83.86M	-$3.54	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A

27.7% of Alaunos Therapeutics shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Artiva Biotherapeutics beats Alaunos Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Alaunos Therapeutics compare to MediWound?

MediWound (NASDAQ:MDWD) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

MediWound currently has a consensus price target of $34.00, indicating a potential upside of 138.76%. Given MediWound's stronger consensus rating and higher possible upside, analysts clearly believe MediWound is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MediWound has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.07, indicating that its stock price is 207% less volatile than the broader market.

46.8% of MediWound shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, MediWound's average media sentiment score of 0.00 equaled Alaunos Therapeutics'average media sentiment score.

Company	Overall Sentiment
MediWound	Neutral
Alaunos Therapeutics	Neutral

Alaunos Therapeutics has lower revenue, but higher earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.79	-$23.88M	-$2.26	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A

Alaunos Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -180.30%. MediWound's return on equity of -67.22% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-180.30%	-67.22%	-31.87%
Alaunos Therapeutics	N/A	-165.94%	-123.50%

Summary

MediWound beats Alaunos Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Alaunos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TCRT vs. The Competition

Export

Metric	Alaunos Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$54.22M	$2.99B	$6.66B	$12.38B
Dividend Yield	N/A	1.78%	2.68%	5.68%
P/E Ratio	-1.01	18.67	24.48	24.42
Price / Sales	N/A	682.46	577.04	128.85
Price / Cash	N/A	56.55	44.20	55.24
Price / Book	2.31	4.04	10.70	6.58
Net Income	-$4.18M	$75.79M	$3.57B	$337.29M
7 Day Performance	-2.71%	0.16%	0.56%	0.55%
1 Month Performance	-15.35%	1.86%	3.57%	4.43%
1 Year Performance	-46.25%	24.73%	28.49%	31.16%

Alaunos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TCRT Alaunos Therapeutics	0.2311 of 5 stars	$2.15 -3.2%	N/A	-39.3%	$54.22M	N/A	N/A	40	Short Interest Increase
IMDX Oncocyte	2.2919 of 5 stars	$5.43 -5.7%	$12.00 +121.0%	N/A	$185.99M	$4.05M	N/A	120
CGEN Compugen	3.4648 of 5 stars	$2.04 +4.1%	$5.00 +145.1%	+20.6%	$185.32M	$72.76M	5.51	70	News Coverage Gap Up
JMAC Maxpro Capital Acquisition	N/A	$13.79 -3.6%	N/A	+123.8%	$185.17M	N/A	N/A	2,021	Gap Down
ARTV Artiva Biotherapeutics	4.2044 of 5 stars	$8.00 +7.8%	$39.00 +387.5%	+452.2%	$183.40M	$250K	N/A	81	Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TCRT) was last updated on 6/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alaunos Therapeutics (TCRT) Competitors

TCRT vs. IMDX, CGEN, JMAC, ARTV, and MDWD

How does Alaunos Therapeutics compare to Oncocyte?

Summary

How does Alaunos Therapeutics compare to Compugen?

Summary

How does Alaunos Therapeutics compare to Maxpro Capital Acquisition?

Summary

How does Alaunos Therapeutics compare to Artiva Biotherapeutics?

Summary

How does Alaunos Therapeutics compare to MediWound?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT vs. The Competition

Alaunos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alaunos Therapeutics (TCRT) Competitors

TCRT vs. IMDX, CGEN, JMAC, ARTV, and MDWD

How does Alaunos Therapeutics compare to Oncocyte?

Do institutionals & insiders have more ownership in IMDX or TCRT?

Which has more volatility & risk, IMDX or TCRT?

Which has better valuation and earnings, IMDX or TCRT?

Does the media favor IMDX or TCRT?

Is IMDX or TCRT more profitable?

Do analysts rate IMDX or TCRT?

Summary

How does Alaunos Therapeutics compare to Compugen?

Does the media refer more to TCRT or CGEN?

Which has more volatility & risk, TCRT or CGEN?

Is TCRT or CGEN more profitable?

Which has preferable valuation & earnings, TCRT or CGEN?

Do institutionals and insiders believe in TCRT or CGEN?

Do analysts prefer TCRT or CGEN?

Summary

How does Alaunos Therapeutics compare to Maxpro Capital Acquisition?

Does the media prefer JMAC or TCRT?

Which has more volatility & risk, JMAC or TCRT?

Which has better valuation & earnings, JMAC or TCRT?

Is JMAC or TCRT more profitable?

Do analysts recommend JMAC or TCRT?

Do insiders and institutionals believe in JMAC or TCRT?

Summary

How does Alaunos Therapeutics compare to Artiva Biotherapeutics?

Which has more risk and volatility, ARTV or TCRT?

Does the media prefer ARTV or TCRT?

Do analysts recommend ARTV or TCRT?

Is ARTV or TCRT more profitable?

Which has higher earnings and valuation, ARTV or TCRT?

Do insiders & institutionals believe in ARTV or TCRT?

Summary

How does Alaunos Therapeutics compare to MediWound?

Do analysts rate MDWD or TCRT?

Which has more volatility & risk, MDWD or TCRT?

Do institutionals and insiders believe in MDWD or TCRT?

Does the media favor MDWD or TCRT?

Which has stronger earnings and valuation, MDWD or TCRT?

Is MDWD or TCRT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT vs. The Competition

Alaunos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools